{"id":"leuprorelin-acetate-microspheres-for-injection","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Hot flashes"},{"rate":"10-30","effect":"Injection site reaction"},{"rate":"20-40","effect":"Decreased libido"},{"rate":"20-40","effect":"Erectile dysfunction"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Bone pain (initial flare)"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leuprorelin binds to GnRH receptors in the pituitary gland, initially stimulating LH and FSH release, but with continuous exposure causes downregulation of GnRH receptors and sustained suppression of gonadotropins. This results in profound reduction of testosterone (in males) or estrogen (in females), making it effective for hormone-dependent conditions. The microsphere formulation provides sustained release over weeks to months.","oneSentence":"Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:44.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT05122377","phase":"","title":"RWE About QOL and Compliance of Patients With OFS in China","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-03-01","conditions":"Breast Cancer, Quality of Life, Hormone Receptor-positive Breast Cancer","enrollment":562},{"nctId":"NCT06449027","phase":"PHASE3","title":"Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-08-21","conditions":"Breast Cancer Subjects","enrollment":211},{"nctId":"NCT00598312","phase":"PHASE3","title":"Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer","status":"COMPLETED","sponsor":"Oakwood Laboratories, LLC","startDate":"2007-04","conditions":"Prostate Cancer","enrollment":201}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tamoxifen Citrate Tablets"],"phase":"phase_3","status":"active","brandName":"Leuprorelin Acetate Microspheres for Injection","genericName":"Leuprorelin Acetate Microspheres for Injection","companyName":"Changchun GeneScience Pharmaceutical Co., Ltd.","companyId":"changchun-genescience-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}